SEC Form 4 · accession 0001493152-26-039528
INTERPACE BIOSCIENCES, INC. · IDXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas W. Burnell
Officer — CEO, President & Chairman · Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 20, 2026 · 5:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001054102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 20, 2026 | M | 1,966,763 | $0.00 | A | 2,037,645 | D | |
| Common StockF2 | Aug 20, 2026 | F | 581,718 | $1.61 | D | 1,455,927 | D | |
| Common Stock | holding | — | — | — | 10,885 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Aug 20, 2026 | A | 1,966,763 | A | — | — | Common Stock | 1,966,763 | 1,966,763 | D |
| Restricted Stock UnitsF3,F4 | — | Aug 20, 2026 | M | 1,966,763 | D | — | — | Common Stock | 1,966,763 | 0 | D |
| Stock Option (right to buy)F5 | $2.02 | Aug 20, 2026 | A | 554,018 | A | — | Aug 20, 2036 | Common Stock | 554,018 | 554,018 | D |
Explanation of responses
- F1Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.
- F2Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations.
- F3Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
- F4On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.
- F5The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.